{"url_path":"/sec/arct/8-k/2026-06-05/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-05","source_url":"https://www.sec.gov/Archives/edgar/data/1768224/0001193805-26-000770-index.html","accession_number":"0001193805-26-000770","cik":"0001768224","ticker":"ARCT","issuer_name":"Arcturus Therapeutics Holdings Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1768224/0001193805-26-000770-index.html","primary_entity_key":"0001768224","primary_entity_name":"Arcturus Therapeutics Holdings Inc."},"word_count":470,"has_tables":true,"body_markdown":"**Item 5.07**\n**Submission of Matters to a Vote of Security Holders.**\n\n \n\nOn June 5, 2026, Arcturus\nTherapeutics Holdings Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Meeting”).The total\nnumber of shares of common stock, par value $0.001 per share, entitled to vote at the Meeting was 28,423,069 and there were present at\nthe Meeting, in person or by proxy, 21,435,189 shares, which constituted a quorum for the Meeting.\n\n \n\nAt the Meeting, the stockholders\nvoted on the following proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with\nthe SEC on April 24, 2026 (the “Proxy Statement”):\n\n \n\n(1) To elect Dr. Peter Farrell,\nJoseph E. Payne, James Barlow, Dr. Edward W. Holmes, Dr. Magda Marquet, Dr. Jing L. Marantz, Dr. John Markels, and Dr. Moncef Slaoui to\nthe Board of Directors, to serve until the Company’s annual meeting of stockholders;\n\n \n\n(2) To approve, on a non-binding\nadvisory basis, the resolution approving named executive officer compensation; and\n\n \n\n(3) To ratify the appointment\nof Deloitte & Touche LLP (“Deloitte”), as the Company’s independent registered public accounting firm for the fiscal\nyear ending December 31, 2026.\n\n \n\nThe final results of the stockholder\nvotes at the Meeting are set forth below:\n\n \n\nProposal No. 1\n\n \n\n  \nFor \nWithhold \nBroker Non-Votes\n\nApproval of the election of the following individuals as directors of the Company, as provided in Proposal Number 1 of the Proxy Statement: \n    \n    \n   \n\n(1) Dr. Peter Farrell \n 15,641,369  \n 116,895  \n 5,676,925 \n\n(2) Joseph E. Payne \n 15,660,970  \n 97,294  \n 5,676,925 \n\n(3) James Barlow \n 15,618,263  \n 140,001  \n 5,676,925 \n\n(4) Dr. Edward W. Holmes \n 15,521,066  \n 237,198  \n 5,676,925 \n\n(5) Dr. Magda Marquet \n 15,616,156  \n 142,108  \n 5,676,925 \n\n(6) Dr. Jing L. Marantz \n 15,626,241  \n 132,023  \n 5,676,925 \n\n(7) Dr. John H. Markels \n 15,633,667  \n 124,597  \n 5,676,925 \n\n(8) Dr. Moncef Slaoui \n 15,643,492  \n 114,772  \n 5,676,925 \n\n \n\nEach of the nine nominees\nwas elected to the Board, each to hold office until the Company’s 2027 annual meeting of stockholders and until their respective\nsuccessors are elected and qualified. \n\n  \n\nProposal No. 2\n\n \n\n  \nFor \nAgainst \nAbstain \nBroker Non-Votes\n\nApproval, on a non-binding advisory basis, the resolution approving named executive officer compensation, referred to as “say-on-pay,” as provided in Proposal Number 2 of the Proxy Statement: \n 15,254,240  \n 327,647  \n 176,375  \n 5,676,927 \n\n \n\nThe proposal was approved. \n\n \n\nProposal No. 3\n\n \n\n  \nFor \nAgainst \nAbstain \nBroker Non-Votes\n\nApproval of the ratification of the appointment of Deloitte as the Company’s independent registered public accounting firm for the year ending December 31, 2026, as provided in Proposal Number 3 of the Proxy Statement: \n 21,378,017  \n 46,823  \n 10,349  \nN/A\n\n \n\nThe appointment was ratified. \n\n  \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements\nof the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto\nduly authorized.\n\n \n\n \n**Arcturus Therapeutics Holdings Inc.**\n\nDate: June 5, 2026\n \n\n \n \n \n\n \nBy:\n\n/s/ Joseph E. Payne\n\n \nName:\nJoseph E. Payne\n\n \nTitle:\nChief Executive Officer"}